LL2-00 hindsight check: Acknowledgements, Preface, Ch 1 Introduction, Part A introduction#

Late lessons from early warnings: science, precaution, innovation (EEA Report No 1/2013), report pp. 1–16. Hindsight window: 2013 to late September 2026. Checked against the digest (digests/LL2-00.md) and the source extract (text/chunks/LL2-00.txt).

Method note. The session’s web-search allowance ran out at the start of this task. Evidence was therefore gathered by fetching primary sources directly: regulator pages, legal texts, treaty records, court and agency documents and journal records (via Crossref, OpenAlex, PubMed and Semantic Scholar lookups of known works). Wikipedia wikitext was used only to find primary references. Items resting only on news or secondary sources are marked [secondary]. The search limit means that post-2013 critiques I did not already know of may be missing. That gap matters most for claim 1 (re-analyses of false positives).

Scope note. This section is front matter. Most of its claims summarise later chapters (Ch 2 and Chs 3–28), whose evidence is not shown on pp. 1–16. The check below therefore covers two things: how the section’s headline claims fared, and how its framework was received and taken up. The section contains no case updates, but its contents page (p. 4) points to Annex 3 (p. 747), An update of some case studies from Vol 1, which I did not open under this task’s file limits.

Overview#

Harm evidence has mostly strengthened. Hindsight since 2013 has been kinder to the section’s health-harm core than to its political and economic claims.

• Most Part A cases. Evidence of harm has grown and regulation has followed. Lead’s burden estimates keep rising, and leaded petrol ended worldwide in 2021. PCE is now IARC Group 2A, and the US adopted a TSCA phase-out in 2024. Second-hand smoke is estimated to cause over 1.6 million deaths a year, and the EU extended smoke-free policy in 2024. The US began a TSCA risk evaluation of vinyl chloride, and OSHA cut the beryllium limit tenfold. DDT is now IARC Group 2A.
• Persistent chemicals. The preface’s warning about persistent, bioaccumulative chemicals and vulnerable exposure windows (p. 7) is the section’s best-vindicated claim. PFAS became the defining post-2013 example, and in 2026 the Commission put the cost of inaction at about EUR 440 billion to 2050. Persistence also became a formal EU hazard class.
• BPA. It moved toward vindication in the EU (EFSA 2023; EU ban 2024) but is still contested internationally (BfR, EMA, US FDA). Calling it a settled “false negative” (p. 10) goes beyond the evidence, as the report itself implies on p. 8.

The emerging-technology warnings have a mixed record.

• Mobile phones. A WHO-commissioned systematic review (2024) found moderate-certainty evidence of no increased brain-tumour risk in humans. A companion animal review (2025) rated evidence of tumours in male rats as high-certainty.
• GM crops. The US National Academies (2016) found no substantiated difference in health risk. In 2026 the EU relaxed rules for one class of gene-edited plants.
• Nuclear accidents. UNSCEAR found no documented health effects among Fukushima residents directly attributable to radiation. A modelling study argues that long-term relocation after Fukushima was not justified on radiological grounds.
• Invasive species. The warning was borne out: IPBES (2023) found annual costs above USD 423 billion. The EU acted with a 2014 regulation.
• Nanomaterials. Specific hazards were flagged for specific forms (one carbon nanotube; the food additive E171). No broad pattern of harm emerged, and the EU took early, partly precautionary steps.

The political-economy claims are contested.

• Precaution and innovation. The claim that wider precaution “can avert harm and stimulate innovation” (p. 11) matches the weak Porter hypothesis: regulation induces innovation, and meta-analytic support is mixed but real. It does not establish net competitiveness gains.
• The EU policy climate turned. From about 2019 to 2026 EU policy moved toward an “innovation principle” and competitiveness. The 2024 Draghi report said precaution “may, as a side effect, restrain innovation”, and chemicals simplification followed in 2025.
• False positives. The “4 of 88” ratio was taken up uncritically (for example by the European Parliament’s research service in 2015). I found no independent replication, and the conceptual objections to it stand.

The corporate-responsibility framing needs qualification. Several major post-2013 exposure disasters were driven mainly by public bodies. The Flint water crisis was “a story of government failure”. Camp Lejeune’s PCE/TCE-contaminated water was supplied by the US military. Japan’s courts had already found the state liable for Minamata. The claim that the law fails victims (p. 11) was repeatedly borne out: time bars defeated Minamata claims in 2024, and Congress had to override statutes of repose for Camp Lejeune in 2022.

The trust claim is weakened. Cologna et al. (2025; 68 countries, n = 71,922) found “no widespread lack of trust in scientists”. US trust fell after 2020, but for reasons (pandemic politics, partisanship) that the preface’s mechanism does not capture.

Net weight for use as a lens. The section’s procedural and structural lessons have held up and were partly institutionalised. They include:

• distinguishing inaction under strong evidence from decisions under uncertainty;
• treating persistence and developmental windows as grounds for early action;
• regulatory independence and transparency of evidence;
• asking who bears costs and who can obtain remedy.

The strongest normative claims should carry less weight: that false alarms are rare, that precaution reliably stimulates innovation, that harm is “for the most part” corporate, and that science is losing public support. They are asserted, based on a curated set of failure cases, or contradicted by later evidence.

Claim 1. False positives are “few and far between”; careful precaution can stimulate innovation#

Original claim (p. 10; resting on Ch 2, p. 17; preface p. 8 says “80 or so”). Part A opens with an analysis showing that regulatory false positives “are few and far between as compared to false negatives”. Of 88 alleged false positives, 4 were confirmed. “Carefully designed precautionary actions can stimulate innovation, even if the risk turns out not to be real or as serious as initially feared.”

Subsequent developments

• Policy uptake without re-testing. The European Parliamentary Research Service’s 2015 briefing on the precautionary principle repeats the Hansen and Tickner result: “four of the 88 cases led to unnecessary measures and … there was little risk of false positives”. It presents this as the answer to fears of “superfluous precautionary measures” (EPRS, Bourguignon, Dec 2015). I found no independent re-analysis that replicated or overturned the 88/4 count.
• The main objections are conceptual and remain unanswered. Nothing in the chapter supplies a common denominator of all precautionary actions. The alleged cases were compiled and classified by the authors. A “false positive” requires the regulation to be shown later to be unnecessary, which is itself hard to establish.
• Critics of how precaution is applied. Löfstedt (2014) argued that a formal review of the EU’s use of the precautionary principle was “long overdue”. Garnett and Parsons (2017), reviewing 15 EU laws and judgments, found that the decision to invoke precaution is “poorly defined”. They found the Commission’s 2000 guidance “was not followed consistently in forming legislation”, though courts more consistently required “plausible evidence of potential hazard”. This does not refute the 88/4 ratio. It does show that the precaution being counted is heterogeneous, which weakens any headline ratio.
• Post-2013 cases in the report’s own emerging-issues set. Some cases now look over-cautious in hindsight. Whether they count as regulatory false positives under Ch 2’s definition is arguable.
• GM crops. The US National Academies (2016) found “no substantiated evidence of a difference in risks to human health” between commercialised GE crops and conventional crops, and no conclusive cause-and-effect evidence of environmental harm. The EU has since relaxed its approach for “NGT1” gene-edited plants (Regulation (EU) 2026/1388, in force 16 July 2026).
• Nuclear-accident relocation. Waddington et al. (2017) used a single cost-benefit metric, the J-value, and concluded that it did “not support the relocation of the 160,000 people moved out on a long-term basis after” Fukushima. Relocation “should be used sparingly if at all”. UNSCEAR (2020/2021 report) found “no adverse health effects among Fukushima Prefecture residents … directly attributable to radiation exposure”. This is a modelling argument, not a consensus.
• Mobile phones. Human evidence has become reassuring (claim 9). Most precautionary measures here were informational, so the cost of any false positive was small.
• The innovation half of the claim.
• Regulation that induces clean-technology innovation (the weak Porter hypothesis) is supported. Dechezleprêtre and Sato (2017) find regulations “induce innovation in clean technologies”, but “the resulting benefits do not appear to be large enough to outweigh the costs of regulations for the regulated entities”. Cohen and Tubb’s (2018) meta-analysis of 103 studies and more than 2,000 estimates finds “considerable heterogeneity”. Positive effects are more likely at country level, but “the most likely scenario is statistical insignificance”.
• Substitution after restriction can work. When the US EPA restricted PCE in 2024, it found that for most prohibited uses “alternative products with similar costs and efficacy to PCE are reasonably available”.
• Substitution can also be regrettable. The EU’s 2024 BPA ban was drafted to cover other hazardous bisphenols to prevent this, and Hansen et al. (2024) flag the same risk for PFAS.

Verdict: contested. The rarity of documented regulatory false positives has not been refuted, but it has not been independently tested either. The ratio still circulates in policy documents as if it were settled. The innovation claim holds in its weak form (regulation can induce substitution and cleaner technology), not in the stronger form that precaution pays for itself.

Implications for weight. Use the section’s point as a caution against assuming that false alarms are common. That is Transferable insight 9, “suggestive”. Do not use “4 of 88” as a quantitative base rate. For a lens on new technologies, the durable points are these: the costs of false positives and false negatives are observed very unequally, since forgone benefits are hard to see; and precaution designed around substitution and alternatives (lesson 7, p. 11) is more defensible than precaution that simply blocks.

Claim 2. Nine Part A false negatives: “more than sufficient evidence for much earlier action”, obstructive business, and the value of independent science#

Original claim (p. 10). Nine chapters (lead, PCE, Minamata, beryllium, second-hand smoke, vinyl chloride, DBCP, BPA, DDT) yield three themes. There was “more than sufficient evidence for much earlier action”. Businesses behaved slowly and “sometimes obstructive[ly]”. Independent research and risk assessment proved valuable.

Subsequent developments, case by case

Obstruction and independence.

• Later evidence adds little that tests the obstruction theme directly. The documented histories stand, and nothing found overturns them.
• The BPA case shows that “independent” assessors can reach 1,000-fold different conclusions from the same literature. EFSA, BfR, EMA and FDA are all public bodies. Independence from producers (lesson 10) is therefore necessary but not sufficient for agreement. The report’s own panel 4.1, on divergent assessments from the same data (p. 16), anticipates this.

Verdict: partly held up. For seven of the nine cases, harm evidence has strengthened and regulation has followed; for lead, PCE, second-hand smoke and DDT’s hazard, strongly so. BPA remains contested, so “all nine” overstates the evidence. DDT’s history involves a real benefit-risk trade-off. “More than sufficient evidence for much earlier action” is a hindsight judgment. Later evidence confirms the harms but cannot show what was knowable and actionable at the time.

Implications for weight. Give strong weight to Transferable insight 1 (distinguish failing to act on strong evidence from deciding under uncertainty) and insight 5 (persistence and developmental windows). Treat “obstructive business” as a recurring but not universal pattern; the beryllium standard of 2012–2017 is a partial counter-example. Treat BPA as the exemplar of contested evidence, not of settled failure.

Claim 3. “By and large, societies are not making the most use of the costly lessons”; the reasons for delay#

Original claim (pp. 10–11). Part C (Chernobyl/Fukushima, GM crops, invasive species, mobile phones, nanotechnology) shows that societies are not using historical lessons. Delay comes from:

• the novelty of the issues;
• poorly or inconsistently evaluated information;
• “strong opposition by the corporate and scientific establishments of the day”;
• institutions that favour the status quo and the short term.

Subsequent developments

• PFAS as the post-2013 test case, supporting the claim. Hansen et al. (2024; Ch 2’s authors) conclude that persistence was recognised decades ago but regulation came only “in the last few years”. They find EU and US frameworks “not … suited to group-based assessments”, with “too little emphasis … on using persistency as a crucial early warning property”.
• A group restriction covering over 10,000 PFAS was proposed only in January 2023.
• The Commission’s January 2026 study puts continued PFAS pollution at about EUR 440 billion to 2050 and water treatment alone at over EUR 1 trillion.
• Status-quo institutions and slow reform, supporting the claim.
• The EU REACH revision promised in the 2020 Chemicals Strategy went to consultation in January 2022. As of the Commission’s page fetched in September 2026, it was still described as “currently revising”.
• Member States repeatedly granted “emergency authorisations” for restricted neonicotinoids after 2013. EFSA found alternatives available for about a third of the products concerned (Commission neonicotinoids page).
• In the US, the 2024 PCE rule was opened for reconsideration in July 2025 under a deregulatory executive order.
• Mixed or contrary evidence for the named technologies.
• Invasive species. A lesson was applied: the EU’s Invasive Alien Species Regulation (EU) 1143/2014 now strictly regulates 114 species. The problem is nonetheless growing: IPBES (4 Sep 2023) counts over 37,000 established alien species and says invasives had a “key role in 60%” of recorded extinctions, at costs above USD 423 billion a year.
• GM crops. The EU applied precaution heavily rather than too little. The CJEU ruled in 2018 (C-528/16) that mutagenesis organisms are GMOs. The later reversal for NGT1 plants (2026) is a move away from precaution after hazard evidence proved reassuring (NASEM 2016).
• Mobile phones and nanotechnology. See claim 9. Human evidence on mobile phones is now largely reassuring. For nanomaterials, the EU took early steps (nano-specific REACH information requirements, Reg. (EU) 2018/1881).
• Nuclear. UNSCEAR’s finding and the relocation debate (claim 1) complicate a simple “lessons unheeded” narrative.
• Scientific establishments as a cause of delay. Evidence is thin but illustrative. On BPA, national assessors (BfR) and EMA resisted EFSA’s lower TDI. This could be read as establishment conservatism or as legitimate scientific disagreement. Conversely, regulatory scientists at BfR argue that the EU system has already made mass poisonings “an issue of the past” and question whether the Chemicals Strategy’s hazard-based turn is “rooted in sound scientific evidence” (Herzler et al. 2021). That is a direct counter-narrative to “lessons not used”.

Verdict: partly held up. For persistent chemicals, the diagnosis was borne out; PFAS is almost a textbook repeat. For several of the named emerging technologies it was not: the dominant post-2013 story for GM and mobile phones is reassuring evidence, and for GM and nuclear relocation there are arguable cases of over-caution. The catalogue of delay mechanisms remains a useful checklist, but the evidence for it comes from cases chosen as failures.

Implications for weight. Keep Transferable insight 6 (recurring causes of delay) as a checklist of mechanisms, with its “moderate” rating. Do not carry forward the implication that all novel technologies are under-regulated: the hindsight record shows both under- and over-reaction. The most transferable element is institutional: status-quo bias, short-termism and case-by-case assessment of large substance classes all slowed action.

Claim 4. Harms “for the most part” caused by “irresponsible corporations”, compounded by government decision practice and legal failure to compensate#

Original claim (p. 11). “The historical chapters illustrate numerous harms which for the most part have been caused by irresponsible corporations.” This fact is “coupled with” shortcomings in how governments decide when to act and in how the law compensates victims.

Subsequent developments

• State-led harm cases.
• Flint water crisis (from 2014). This was lead exposure caused by public authorities. The Flint Water Advisory Task Force (March 2016) called it “a story of government failure, intransigence, unpreparedness, delay, inaction, and environmental injustice”, and found the Michigan Department of Environmental Quality “bears primary responsibility”.
• Camp Lejeune. Water contaminated with PCE and TCE, and supplied by or for the United States, reached people from 1953 to 1987. Litigation was dismissed on a state statute of repose in 2016 [secondary]. Congress then legislated a cause of action that overrides “any applicable statute of repose or statute of limitations” (PACT Act, Pub. L. 117-168, s. 804, 10 Aug 2022).
• Minamata. Japan’s Supreme Court (15 Oct 2004) had already held the national government and Kumamoto Prefecture liable for failing to use their regulatory powers after 1959. This predates the report but shows that “irresponsible corporation” is only part of the causal story.
• Other public actors. DDT use has been driven largely by public-health programmes (Stockholm Annex B; DDT Register). Nuclear-accident harms involve utilities and states.
• Corporate conduct is still central in other cases. The PFAS history (Hansen et al. 2024, drawing on company documents) and the EU’s 2026 cost estimates keep corporate responsibility central for persistent chemicals.
• Legal failure to compensate, repeatedly confirmed.
• The Kumamoto District Court (22 Mar 2024) found 25 plaintiffs had Minamata disease but dismissed their claims [secondary].
• A resident health survey required by Japan’s 2009 Minamata special measures act had still not been carried out by 2025 [secondary, KKT/NTV via ja.wikipedia].
• Camp Lejeune victims needed a special Act of Congress.
• In Flint, a USD 600 million settlement with the State of Michigan was announced in August 2020, while most criminal charges against officials were dismissed or dropped [secondary].

Verdict: partly held up. The legal-remedy half is borne out strongly. The “for the most part … irresponsible corporations” generalisation is weaker. It may describe the report’s selected historical chapters, but post-2013 cases show public authorities and publicly run systems as primary causes. It also sits oddly with the report’s own Minamata chapter, where state liability is judicial fact.

Implications for weight. Keep Transferable insight 7 (producers obstruct and manufacture doubt) as a pattern. The better-supported generalisation is about the actor with control over exposure and information, whether a firm, a utility or a public agency. Such an actor has incentives to reassure and delay, and remedies are structurally weak for victims: time bars, burden of proof, latency. Insight 11 (costs and remedies skewed against those harmed) is strengthened by 2013–2026 events.

Claim 5. Wider use of the precautionary principle “can avert harm and stimulate innovation”; late lessons are “highly pertinent” to crises in finance, climate, energy and food#

Original claim (p. 11; see also the preface, p. 7, on the lessons being “directly applicable” to “financial and economic risks”).

Subsequent developments

• The Porter-hypothesis evidence.
• Ambec et al. (2013) review twenty years of work and find “conflicting evidence”. They distinguish the weak version (regulation spurs innovation), which has reasonable support, from the strong version (net competitiveness gains), which does not.
• Cohen and Tubb (2018): “the most likely scenario is statistical insignificance”, with positive effects more likely at country level.
• Dechezleprêtre and Sato (2017): regulation induces clean innovation, but the benefits do not outweigh regulated firms’ costs.
• Overall, “can … stimulate innovation” is defensible; “precaution pays” is not established.
• EU policy after 2013 moved in two directions.
• Toward precaution:
  • the 2013 neonicotinoid restrictions, and a full outdoor ban in May 2018;
  • the 2020 Chemicals Strategy for Sustainability, with an “essential use” concept proposed in April 2024;
  • new CLP hazard classes (proposed 19 Dec 2022) covering endocrine disruption, PBT/vPvB and PMT/vPvM;
  • the BPA ban (2024);
  • the “one substance, one assessment” package (in force 1 Jan 2026).
• Away from precaution:
  • industry associations wrote an “innovation principle” and got it into EU texts. Garnett, Van Calster and Reins (2018) call this “the first time an industry association has successfully tried to introduce a new principle into the EU’s legal order”;
  • the 2024 Draghi report says the EU’s “stringent regulatory environment (exemplified by policies based on the precautionary principle) may, as a side effect, restrain innovation”, and calls for a “right balance between the principle of precaution and the principle of innovation”;
  • a Chemicals Industry Action Plan followed in July 2025, and REACH revision and simplification remain pending;
  • the NGT Regulation (2026) relaxes precaution for one category of plants.
• Finance and climate. The claim that the lessons are pertinent to finance was taken up. Chenet, Ryan-Collins and van Lerven (2021; cites the report) propose a “‘precautionary’ financial policy approach” to climate-related financial risk, under “radical uncertainty”. This is advocacy scholarship, not evidence that precautionary finance works.

Verdict: contested. “Avert harm” is supported where action was eventually taken on strong evidence (leaded petrol, smoke-free laws). There the benefits of acting are now large and well documented, which implies that earlier action would have averted more. “Stimulate innovation” is supported only weakly, and the EU policy climate of 2019–2026 increasingly framed precaution as a cost to innovation. Whether the lessons are pertinent to finance, energy and food is a framing claim. It has been adopted by some scholars but not tested.

Implications for weight. Insight 10 (precaution can drive innovation via substitution) should stay “suggestive”. The section’s more robust move is to make precaution about alternatives (lesson 7). That turns precaution–innovation into a design question, not a trade-off; the substitution examples (PCE wet cleaning) support it, and regrettable substitution (bisphenols, PFAS) limits it. Expect this claim to face organised counter-framing (“innovation principle”) in any contemporary application. That counter-framing is itself a pattern the report’s knowledge–power thesis (p. 7) would predict.

Claim 6. “The scientific elites have also been slowly losing public support”, partly through “misplaced certainty about the absence of harm”#

Original claim (p. 6). The preface offers no evidence for the trend or the mechanism.

Subsequent developments

• Cross-national level. Cologna et al. (Nature Human Behaviour, published 20 Jan 2025) surveyed 71,922 respondents in 68 countries (Nov 2022–Aug 2023). They found “in most countries, most people trust scientists” and “no widespread lack of trust in scientists”. The authors caution that distrust “by even a small minority” can matter for policy. As the task notes, this is a cross-sectional survey and does not test a decline or its causes.
• Trend (US only, the longest consistent series).
• Pew found 87% of Americans had at least a fair amount of confidence in scientists to act in the public interest in April 2020. This fell to 73% (Oct 2023), then 76% (Nov 2024) and 77% (Jan 2026).
• The fall was driven mainly by Republicans (85% in April 2020 to about 65%). The partisan gap is “far wider than … before the COVID-19 pandemic” (Pew, 14 Nov 2024; 15 Jan 2026).
• This is a decline, but it follows 2020 and is associated with partisanship and pandemic politics, not with “misplaced certainty about the absence of harm”.
• Mechanism. Experimental evidence bears on the remedy the preface implies, openness about uncertainty. Across five experiments (n = 5,780), communicating uncertainty produced “only a small decrease in trust in numbers and trustworthiness of the source” (van der Bles et al. 2020). So acknowledging uncertainty costs little trust. That supports candour, but it does not show that false reassurance is what erodes trust.

Verdict: weakened. The best global evidence does not support a general loss of public support for scientists. The observed US decline has a different timing and different correlates from those the preface proposes, and I found no evidence testing the “misplaced certainty” mechanism.

Implications for weight. Keep Transferable insight 3 (confident “no harm” claims under incomplete evidence are a recurrent decision failure). Separate it from the unevidenced trust-erosion story. In a contemporary lens, the defensible claim concerns decision quality and accountability, not a documented legitimacy crisis for science.

Claim 7. Persistent, bioaccumulative chemicals and “small dose exposures” in foetal and childhood windows can be “devastating”; BPA as false negative (p. 10) vs “contested” (p. 8)#

Original claim (p. 7; BPA on pp. 8 and 10).

Subsequent developments

• Persistence as an early warning.
• The EU introduced hazard classes for persistent, bioaccumulative and mobile substances (PBT/vPvB, PMT/vPvM) and for endocrine disruptors in CLP (Commission proposal and delegated act, Dec 2022).
• The Stockholm Convention kept adding persistent chemicals, including PFOA (decision SC-9/12) and PFHxS (SC-10/13).
• The Commission’s 2026 PFAS cost study states that “since PFAS remain in human bodies and the environment for decades … early action is vital”. That is close to the preface’s own reasoning.
• Developmental windows and low doses.
• EFSA’s 2020 PFAS opinion set a group TWI of 4.4 ng/kg bw/week. It took “decreased response of the immune system to vaccination” as the critical effect and found that exposure in pregnancy and breastfeeding drives infant levels.
• Grandjean and Landrigan (2014; Grandjean is a report editor) added six developmental neurotoxicants documented since 2006, including DDT and tetrachloroethylene.
• Lead burden estimates rose (claim 2).
• BPA.
• EFSA 2023: TDI of 0.2 ng/kg bw/day, about 20,000 times lower than the 2015 temporary TDI. Exposure in all age groups exceeds it; BfR describes the excess as “several orders of magnitude”.
• Dissent: BfR (TDI of 200 ng/kg bw/day, “does not support” EFSA’s value), EMA (methodological divergence), US FDA (safe at current levels).
• EU action: Reg. (EU) 2024/3190 bans BPA and other hazardous bisphenols in food-contact materials, building on the thermal-paper ban (2020) and infant-product restrictions (2011, 2018).
• Lemus and Kovacic (2021) show that EFSA’s assessments grew more precise without reducing uncertainty. More evidence increased “indeterminacy” and “ambiguity”.

Verdict: strengthened. The claims about persistence and vulnerable windows are the section’s most clearly vindicated. BPA remains contested on scale among assessors. The EU has acted as if the p. 10 “false negative” label is correct, while other major assessors have not accepted it. The report’s own inconsistency (p. 8 vs p. 10) mirrors a real split that persists in 2026.

Implications for weight. Transferable insight 5 (persistence and vulnerable-window exposure make delay costly and irreversible) can be upgraded from “moderate” to strong as a general mechanism. It is now embedded in EU hazard classification and costed by the Commission. For BPA, the lesson to carry is how contested evidence is governed, not that BPA is a proven false negative.

Claim 8. “100 thousand chemicals” in commerce; conventions and EU laws act top-down through “the main economic actors rather than communities or individuals”#

Original claim (p. 7). The preface also says the Rotterdam Convention covers 24 pesticides, four severely hazardous pesticide formulations and 11 industrial chemicals (39 in total).

Subsequent developments

• Scale. Wang et al. (2020) analysed 22 inventories from 19 countries and regions. They found “over 350 000 chemicals and mixtures of chemicals … registered”, “up to three times as many as previously estimated”. More than 50,000 are claimed confidential and up to 70,000 are ambiguously described. The preface’s figure understated the scale by roughly 3.5 times.
• Rotterdam.
• Annex III now lists 57 chemicals: 38 pesticides (including 4 severely hazardous formulations), 18 industrial chemicals and 1 in both categories.
• Listing requires consensus. Chrysotile asbestos and paraquat formulations are still only “recommended for listing” after repeated Conferences of the Parties.
• This supports the preface’s point that treaty governance is top-down and exposed to veto by producer states.
• REACH performance.
• Of 286 compliance checks in 2018, 211 (74%) ended in draft decisions requesting missing information (ECHA, 2018). These checks target dossiers already of concern, so the figure is not a population rate.
• By March 2019 no eligible authorisation request had been rejected [secondary]. The EU General Court annulled one authorisation in Case T-837/16 (7 Mar 2019) for failing properly to assess alternatives.
• The Candidate List reached 253 substances of very high concern by February 2026 [secondary, via ECHA list].
• The planned REACH revision was still pending in September 2026 (Commission page).
• Communities and individuals. REACH’s Article 33 “consumer right to know” (45-day reply duty) and tools such as the LIFE askREACH project give some bottom-up access (Commission REACH page). Still, the architecture remains registrant-led and authority-led.

Verdict: held up. The top-down, producer-centred character of chemicals governance is unchanged. The number was an underestimate, which strengthens the preface’s concern about scale. The treaty regimes grew but remain limited by consensus.

Implications for weight. The structural point generalises well beyond chemicals. When regulatory information is produced by the regulated party and screened by an under-resourced authority, compliance gaps and slow restriction are predictable (insight 2: how knowledge is funded and produced is a site of power). Treat the “100,000” figure as out of date; cite Wang et al. (2020) instead.

Claim 9. Nanotechnology and mobile phones: “relatively new, largely unknown, yet already widespread”; historical lessons “need to be applied if hazards are to be avoided”#

Original claim (pp. 10, 9). Note: Andrew Maynard is a co-author of Ch 22 (nanotechnology), listed on p. 4.

Subsequent developments

• Mobile phones.
• Human evidence (reassuring). A WHO-commissioned systematic review of human observational studies (Karipidis et al. 2024) found “moderate certainty evidence” that mobile-phone RF exposure to the head “likely does not increase the risk of glioma, meningioma, acoustic neuroma, pituitary tumours, and salivary gland tumours in adults, or of paediatric brain tumours”.
• Animal evidence (concerning). The US NTP (Nov 2018) reported “clear evidence” of heart schwannomas and “some evidence” of brain gliomas in male rats. A companion WHO-commissioned animal review (Mevissen et al. 2025) rated the certainty of evidence as high for increased glioma and heart schwannoma in male rats, though “none of these findings were dose-dependent”. NTP notes that extrapolating to humans “is not straightforward”.
• Nanotechnology.
• Specific hazards. IARC classified MWCNT-7 carbon nanotubes as possibly carcinogenic (Group 2B; Grosse et al. 2014). EFSA (2021) concluded that the food additive titanium dioxide (E171) could “no longer be considered safe”, because genotoxicity could not be ruled out.
• Diverging regulators. The EU withdrew E171 authorisation (Reg. (EU) 2022/63, from Feb 2022). The UK FSA and Health Canada disagreed and did not follow [secondary, via Wikipedia references].
• Early precautionary steps. REACH gained nano-specific information requirements (Reg. (EU) 2018/1881), and the EU nanomaterial definition was revised in 2022 (Commission REACH page).
• I found no evidence of broad population-level harm from nanomaterials as a class.

Verdict: partly held up. “Largely unknown, yet already widespread” was accurate in 2013. Since then, knowledge has grown in a direction that is mostly reassuring for human brain-tumour risk from phones. Nanomaterials show hazards for specific forms and uses, not class-wide harm. The EU did apply some early, proportionate precaution for nanomaterials, as the section urged. For phones, the persistent mismatch between animal and human evidence makes “hazards … to be avoided” still open, but less pressing than implied.

Implications for weight. The procedural lesson survives: deployment ahead of knowledge lets exposure accumulate before the evidence arrives (insight 4). The substantive expectation that such technologies will turn out to be hazardous does not. For a lens, apply the lesson as “build monitoring and characterisation early, differentiate by form and use”, not as a presumption of harm.

Claim 10. The 14 Vol 1 cases and 12 lessons “remain highly pertinent”, including lesson 12’s trigger (“reasonable grounds for concern”)#

Original claim (p. 9; box p. 11). The box’s source line misdates Vol 1 as “1986–2000”; the correct period is 1896–2000.

Subsequent developments: which safeguards were adopted

• Lesson 12 (act on “reasonable grounds for concern”). The trigger was not new in 2013: it echoes the Commission’s 2000 Communication on the precautionary principle, which I found no evidence has been revised. It was applied in the neonicotinoid restrictions (2013) and outdoor ban (2018). It was undercut by repeated national emergency derogations (Commission neonicotinoids page). Its application remains “poorly defined” and inconsistent in legislation (Garnett & Parsons 2017).
• Lesson 10 (regulatory independence, inclusive information). EU Regulation (EU) 2019/1381 requires that commissioned studies be notified to EFSA in advance, supporting studies be published, and EFSA be able to commission “verification” studies in cases of “serious controversies or conflicting results”. This is a direct institutional response to the pattern lesson 10 describes.
• Lessons 1 and 3 (ignorance, uncertainty, blind spots). EFSA’s 2019 Guidance on Communication of Uncertainty in Scientific Assessments cites the 2013 report (OpenAlex citation record). This is evidence of uptake at the agency level. Critics (Löfstedt & Bouder 2017) questioned how far this uncertainty agenda should go.
• Lesson 5 (real-world conditions and susceptible groups). The US TSCA reform of 2016 requires risk evaluations to “consider risks to susceptible and highly exposed populations” and to exclude “consideration of costs or non-risk factors” (EPA summary). Implementation has since swung politically: the 2024 rules were followed by 2025–26 reconsideration.
• Lessons 2 and 11 (monitoring; institutional obstacles). The EU “one substance, one assessment” package (in force 1 Jan 2026) consolidates chemicals data and assessment across agencies. The Commission is preparing an EU-wide PFAS monitoring framework (Jan 2026).
• Reuse of the framework itself. OpenAlex records about 300 works citing Vol 2, against about 760 for Vol 1. They include the 2015 planetary-boundaries update, the “framework for responsible innovation” (Stilgoe et al. 2013), Grandjean and Landrigan (2014) and the PFAS “late lessons” analysis (Hansen et al. 2024). The last applies the approach and finds “too little emphasis” on persistence as an early warning. Much of this uptake comes from the report’s own author network.

Verdict: held up. Events since 2013, above all PFAS, confirm that the lessons remain pertinent. Several procedural safeguards were adopted in recognisable form: evidence transparency and verification, susceptible populations, persistence as a hazard class, uncertainty guidance. Adoption is partial, uneven and reversible, as neonicotinoid derogations, US reconsiderations since 2025 and the EU turn to simplification show.

Implications for weight. The twelve lessons are the section’s most durable content and can serve as procedural criteria in a contemporary lens. Lessons 10 (independence), 12 (acting on reasonable grounds) and 5 (real-world conditions) have clear institutional counterparts to point to. Two cautions apply. Lesson 12’s trigger remains undefined in practice. And the post-2013 record shows these safeguards can be rolled back once competitiveness framing dominates.

Sources#

(Accessed 25 September 2026 unless stated. [secondary] = news or encyclopaedic source used where no primary source could be retrieved.)

Precaution, false positives, innovation - Bourguignon, D. (2015, December). The precautionary principle: Definitions, applications and governance. European Parliamentary Research Service, PE 573.876. https://www.europarl.europa.eu/RegData/etudes/IDAN/2015/573876/EPRS_IDA(2015)573876_EN.pdf - Löfstedt, R. (2014, August). The precautionary principle in the EU: Why a formal review is long overdue. Risk Management 16, 137–163. https://doi.org/10.1057/rm.2014.7 - Garnett, K. & Parsons, D. J. (2017). Multi-case review of the application of the precautionary principle in European Union law and case law. Risk Analysis 37(3), 502–516 (online 18 May 2016). https://doi.org/10.1111/risa.12633 - Garnett, K., Van Calster, G. & Reins, L. (2018, 2 January). Towards an innovation principle: an industry trump or shortening the odds on environmental protection? Law, Innovation and Technology 10(1), 1–14. https://doi.org/10.1080/17579961.2018.1455023 - Löfstedt, R. & Bouder, F. (2017, 27 April). Evidence-based uncertainty analysis: What should we now do in Europe? A view point. Journal of Risk Research. https://doi.org/10.1080/13669877.2017.1316763 - Ambec, S., Cohen, M. A., Elgie, S. & Lanoie, P. (2013). The Porter hypothesis at 20. Review of Environmental Economics and Policy 7(1), 2–22. https://doi.org/10.1093/reep/res016 - Cohen, M. A. & Tubb, A. (2018). The impact of environmental regulation on firm and country competitiveness: a meta-analysis of the Porter hypothesis. JAERE 5(2), 371–399. https://doi.org/10.1086/695613 - Dechezleprêtre, A. & Sato, M. (2017). The impacts of environmental regulations on competitiveness. Review of Environmental Economics and Policy 11(2). https://doi.org/10.1093/reep/rex013 - Draghi, M. (2024, September). The future of European competitiveness, Part B: In-depth analysis and recommendations. European Commission. https://commission.europa.eu/document/download/ec1409c1-d4b4-4882-8bdd-3519f86bbb92_en?filename=The%20future%20of%20European%20competitiveness_%20In-depth%20analysis%20and%20recommendations_0.pdf - Chenet, H., Ryan-Collins, J. & van Lerven, F. (2021, 25 February). Finance, climate-change and radical uncertainty: Towards a precautionary approach to financial policy. Ecological Economics 183, 106957. https://doi.org/10.1016/j.ecolecon.2021.106957 - Herzler, M. et al. (2021, 22 June). The “EU chemicals strategy for sustainability” questions regulatory toxicology as we know it. Archives of Toxicology 95, 2589–2601. https://doi.org/10.1007/s00204-021-03091-3 - Waddington, I., Thomas, P. J., Taylor, R. H. S. & Vaughan, G. J. (2017, November). J-value assessment of relocation measures following the nuclear power plant accidents at Chernobyl and Fukushima Daiichi. Process Safety and Environmental Protection 112, 16–49. https://doi.org/10.1016/j.psep.2017.03.012

Trust in science - Cologna, V., Mede, N. G., Berger, S. et al. (2025, 20 January). Trust in scientists and their role in society across 68 countries. Nature Human Behaviour 9, 713–730. https://doi.org/10.1038/s41562-024-02090-5 - Pew Research Center (2024, 14 November). Public trust in scientists and views on their role in policymaking. https://www.pewresearch.org/science/2024/11/14/public-trust-in-scientists-and-views-on-their-role-in-policymaking/ - Pew Research Center (2026, 15 January). Americans’ confidence in scientists. https://www.pewresearch.org/science/2026/01/15/americans-confidence-in-scientists/ - van der Bles, A. M., van der Linden, S., Freeman, A. L. J. & Spiegelhalter, D. J. (2020, 23 March). The effects of communicating uncertainty on public trust in facts and numbers. PNAS 117(14). https://doi.org/10.1073/pnas.1913678117

Chemicals scale, conventions, REACH, EU chemicals policy - Wang, Z., Walker, G. W., Muir, D. C. G. & Nagatani-Yoshida, K. (2020, 22 January). Toward a global understanding of chemical pollution. Environmental Science & Technology 54(5). https://doi.org/10.1021/acs.est.9b06379 - Rotterdam Convention Secretariat. Annex III Chemicals (57 listed). https://www.pic.int/TheConvention/Chemicals/AnnexIIIChemicals/tabid/1132/language/en-US/Default.aspx - Rotterdam Convention Secretariat. Chemicals recommended for listing in Annex III. https://www.pic.int/TheConvention/Chemicals/Recommendedforlisting/tabid/1185/ - Stockholm Convention Secretariat. All POPs listed. https://www.pops.int/TheConvention/ThePOPs/AllPOPs/tabid/2509/Default.aspx - Stockholm Convention Secretariat. DDT overview. https://chm.pops.int/Implementation/PesticidePOPs/DDT/Overview/tabid/378/Default.aspx - ECHA (2019). Evaluation progress 2018 (archived). https://web.archive.org/web/2019id_/https://echa.europa.eu/dossier-evaluation-progress-2018 - European Commission, DG ENV. REACH Regulation (page fetched Sept 2026). https://environment.ec.europa.eu/topics/chemicals/reach-regulation_en - European Commission, DG ENV. Chemicals Strategy (timeline incl. CLP hazard classes 19 Dec 2022; essential use 22 Apr 2024; OSOA in force 1 Jan 2026). https://environment.ec.europa.eu/strategy/chemicals-strategy_en - European Commission (2026, 29 January). New study confirms huge and growing costs of PFAS pollution. https://environment.ec.europa.eu/news/new-study-confirms-huge-and-growing-costs-pfas-pollution-2026-01-29_en - Wikipedia, “Registration, Evaluation, Authorisation and Restriction of Chemicals” (wikitext, used for Candidate List count, authorisation statistics, T-837/16 reference) [secondary]. https://en.wikipedia.org/wiki/Registration,_Evaluation,_Authorisation_and_Restriction_of_Chemicals - Regulation (EU) 2019/1381 on the transparency and sustainability of the EU risk assessment in the food chain (20 June 2019). https://eur-lex.europa.eu/eli/reg/2019/1381/oj/eng - US EPA. Highlights of key provisions in the Frank R. Lautenberg Chemical Safety for the 21st Century Act (2016). https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/highlights-key-provisions-frank-r-lautenberg-chemical - EFSA Scientific Committee et al. (2019). Guidance on communication of uncertainty in scientific assessments. EFSA Journal 17(1), 5520. https://doi.org/10.2903/j.efsa.2019.5520 - Hansen, S. F., Bunde, C. T. H., Roy, M. A., Tickner, J. A. & Baun, A. (2024, 17 December). Late lessons from early warnings on PFAS. Nature Water 2, 1157–1165. https://doi.org/10.1038/s44221-023-00168-4 - OpenAlex citation record for Late lessons from early warnings: science, precaution, innovation (W2900056899). https://api.openalex.org/works?filter=cites:W2900056899

BPA, PFAS, developmental exposure - EFSA (2023, 19 April). Bisphenol A in food is a health risk. https://www.efsa.europa.eu/en/news/bisphenol-food-health-risk - EFSA. Bisphenol topic page (milestones; Commission ban 19 Dec 2024). https://www.efsa.europa.eu/en/topics/topic/bisphenol - BfR (2023, 19 April). Opinion No 018/2023: Bisphenol A: BfR proposes health based guidance value. https://www.bfr.bund.de/cm/349/bisphenol-a-bfr-proposes-health-based-guidance-value-current-exposure-data-are-needed-for-a-full-risk-assessment.pdf - US FDA. Bisphenol A (BPA): Use in food contact application (content current as of 20 Apr 2023). https://www.fda.gov/food/food-packaging-other-substances-come-contact-food-information-consumers/bisphenol-bpa-use-food-contact-application - European Commission, DG SANTE. Food contact materials legislation (Reg. (EU) 2024/3190). https://food.ec.europa.eu/safety/chemical-safety/food-contact-materials/legislation_en - Lemus, D. & Kovacic, Z. (2021, December). Precise yet uncertain: broadening understandings of uncertainty and policy in the BPA controversy. Risk Analysis. https://doi.org/10.1111/risa.13860 - EFSA (2020, 17 September). PFAS in food: EFSA assesses risks and sets tolerable intake. https://www.efsa.europa.eu/en/news/pfas-food-efsa-assesses-risks-and-sets-tolerable-intake - Grandjean, P. & Landrigan, P. J. (2014, 17 February). Neurobehavioural effects of developmental toxicity. Lancet Neurology 13(3), 330–338. https://doi.org/10.1016/S1474-4422(13)70278-3

Part A cases - UNEP (2021, 30 August). Era of leaded petrol over. https://www.unep.org/news-and-stories/press-release/era-leaded-petrol-over-eliminating-major-threat-human-and-planetary - Lanphear, B. P. et al. (2018, 13 March). Low-level lead exposure and mortality in US adults. Lancet Public Health 3(4). https://doi.org/10.1016/S2468-2667(18)30025-2 - McFarland, M. J., Hauer, M. E. & Reuben, A. (2022, 7 March). Half of US population exposed to adverse lead levels in early childhood. PNAS 119(11). https://doi.org/10.1073/pnas.2118631119 - Larsen, B. & Sánchez-Triana, E. (2023, 11 September). Global health burden and cost of lead exposure in children and adults. Lancet Planetary Health 7(10). https://doi.org/10.1016/S2542-5196(23)00166-3 - US EPA (2023, 20 October). Final finding that lead emissions from aircraft engines … endanger public health and welfare. https://www.epa.gov/regulations-emissions-vehicles-and-engines/regulations-lead-emissions-aircraft - IARC (2014). Monographs Vol 106: Trichloroethylene, tetrachloroethylene and some other chlorinated agents. https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-To-Humans/Trichloroethylene-Tetrachloroethylene-And-Some-Other-Chlorinated-Agents-2014 - US EPA. Risk management for perchloroethylene (PCE) (last updated 27 July 2026). https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-management-perchloroethylene-pce - Public Law 117-168 (2022, 10 August), s. 804, Camp Lejeune Justice Act of 2022. https://www.govinfo.gov/content/pkg/PLAW-117publ168/html/PLAW-117publ168.htm - Wikipedia, “Camp Lejeune water contamination” (2016 MDL dismissal) [secondary]. https://en.wikipedia.org/wiki/Camp_Lejeune_water_contamination - United Nations Treaty Collection. Minamata Convention on Mercury (adopted Kumamoto 10 Oct 2013; in force 16 Aug 2017; 154 parties). https://treaties.un.org/Pages/ViewDetails.aspx?src=TREATY&mtdsg_no=XXVII-17&chapter=27&clang=_en - Asahi Shimbun (2024, 22 March). 水俣病訴訟、熊本地裁は救済対象の拡大認めず 大阪地裁判決から後退 [secondary]. https://www.asahi.com/articles/ASS3Q26DDS3KTLVB005.html - Japanese Wikipedia, 水俣病 (2004 Supreme Court ruling summary; certification statistics citing Nikkei 2021; 2009 Act health survey citing KKT/NTV 2024) [secondary]. https://ja.wikipedia.org/wiki/水俣病 - OSHA (2017, 9 January). Occupational exposure to beryllium; final rule. 82 FR 2470. https://www.federalregister.gov/documents/2017/01/09/2016-30409/occupational-exposure-to-beryllium - Frazer, K. et al. (2016, 3 February). Legislative smoking bans for reducing harms from secondhand smoke exposure. Cochrane Database of Systematic Reviews CD005992.pub3. https://doi.org/10.1002/14651858.CD005992.pub3 - WHO. Tobacco fact sheet (2026). https://www.who.int/news-room/fact-sheets/detail/tobacco - European Commission, DG SANTE. Smoke-free environments (Council Recommendation adopted 3 Dec 2024). https://health.ec.europa.eu/tobacco/smoke-free-environments_en - US EPA. Risk evaluation for vinyl chloride (high-priority designation Dec 2024). https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-evaluation-vinyl-chloride - Wikipedia, “1,2-Dibromo-3-chloropropane” (2009–2010 litigation) [secondary]. https://en.wikipedia.org/wiki/1,2-Dibromo-3-chloropropane - Loomis, D. et al. (2015, 22 June). Carcinogenicity of lindane, DDT, and 2,4-dichlorophenoxyacetic acid. Lancet Oncology 16(8), 891–892. https://doi.org/10.1016/S1470-2045(15)00081-9 - Cohn, B. A. et al. (2015, 16 June). DDT exposure in utero and breast cancer. Journal of Clinical Endocrinology & Metabolism 100(8). https://doi.org/10.1210/jc.2015-1841

Public-authority harms - Flint Water Advisory Task Force (2016, 21 March). Final report. https://www.michigan.gov/-/media/Project/Websites/formergovernors/Folder6/FWATF_FINAL_REPORT_21March2016.pdf - Wikipedia, “Flint water crisis” (2020 settlement; criminal cases) [secondary]. https://en.wikipedia.org/wiki/Flint_water_crisis

Emerging technologies (Part C) - Karipidis, K. et al. (2024, 30 August). The effect of exposure to radiofrequency fields on cancer risk in the general and working population: a systematic review of human observational studies, Part I. Environment International. https://doi.org/10.1016/j.envint.2024.108983 - Mevissen, M. et al. (2025, May). Effects of radiofrequency electromagnetic field exposure on cancer in laboratory animal studies, a systematic review. Environment International 199, 109482. https://doi.org/10.1016/j.envint.2025.109482 - US National Toxicology Program. Cell phone radio frequency radiation (technical reports Nov 2018). https://ntp.niehs.nih.gov/whatwestudy/topics/cellphones - Grosse, Y. et al. (2014, December). Carcinogenicity of fluoro-edenite, silicon carbide fibres and whiskers, and carbon nanotubes. Lancet Oncology 15, 1427–1428. https://doi.org/10.1016/S1470-2045(14)71109-X - Wikipedia, “Titanium dioxide” (EFSA 2021 E171 conclusion; Reg. (EU) 2022/63; UK and Canadian positions) [secondary]. https://en.wikipedia.org/wiki/Titanium_dioxide - National Academies of Sciences, Engineering, and Medicine (2016). Genetically Engineered Crops: Experiences and Prospects, report brief. https://nap.nationalacademies.org/resource/23395/GE-crops-report-brief.pdf - Court of Justice of the EU (2018, 25 July). Press release 111/18, Case C-528/16. https://curia.europa.eu/jcms/upload/docs/application/pdf/2018-07/cp180111en.pdf - European Parliament Legislative Train. Plants produced by certain new genomic techniques (Regulation (EU) 2026/1388; OJ 26 June 2026). https://www.europarl.europa.eu/legislative-train/theme-a-european-green-deal/file-plants-produced-by-certain-new-genomic-techniques - UNSCEAR (2022). 2020/2021 Report, Vol. II, Annex B (Fukushima). https://www.unscear.org/unscear/uploads/documents/unscear-reports/UNSCEAR_2020_21_Report_Vol.II-CORR.pdf - European Commission, DG ENV. Invasive alien species (114 species of Union concern; Reg. (EU) 1143/2014). https://environment.ec.europa.eu/topics/nature-and-biodiversity/invasive-alien-species_en - IPBES (2023, 4 September). Media release: Invasive alien species assessment. https://www.ipbes.net/IASmediarelease - European Commission, DG SANTE. Neonicotinoids (2013 restriction; 2018 outdoor ban; emergency authorisations). https://food.ec.europa.eu/plants/pesticides/approval-active-substances-safeners-and-synergists/renewal-approval/neonicotinoids_en